Iambic Therapeutics Inc. Company Profile
NASDAQ: IAMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Iambic Therapeutics at a glance
Iambic Therapeutics Inc. (NASDAQ: IAM) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in San Diego, CA. Iambic Therapeutics is led by Dr. Thomas Miller Ph.D. and employs about 171 people. The company's shares have traded publicly since 2026.
At a market capitalization of $621.4 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001997038, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Iambic Therapeutics do?
Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.
Business description based on the company's public filings.
Company information
- Legal name
- Iambic Therapeutics Inc.
- Ticker
- NASDAQ: IAM
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Thomas Miller Ph.D.
- Employees
- 171
- Headquarters
- 5627 Oberlin Drive, San Diego, CA, United States
- Phone
- (619) 330-5499
- Website
- iambic.ai
- IPO year
- 2026
- Market cap
- $621.42M
- SEC CIK
- 0001997038
Companies similar to Iambic Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SRZNSurrozen Inc. | 28.46 | -7.21% | $596.40M | vs IAM |
| CGEMCullinan Therapeutics Inc. | 8.89 | -1.98% | $577.15M | vs IAM |
| FDMT4D Molecular Therapeutics Inc. | 10.23 | -4.57% | $576.76M | vs IAM |
| ENTXEntera Bio Ltd. | 3.31 | +0.76% | $575.53M | vs IAM |
| DBVTDBV Technologies S.A. ADR | 9.02 | -4.25% | $566.82M | vs IAM |
| ATTOAttovia Therapeutics Inc. | 15.10 | -3.08% | $690.26M | vs IAM |
| SLDBSolid Biosciences Inc. | 6.25 | -2.95% | $697.57M | vs IAM |
| AURAAura Biosciences Inc. | 6.87 | -1.58% | $714.99M | vs IAM |